Advertisement

Related Videos

Opening Session Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Jun
26
Today In Oncology
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
Multi-Cancer Early Detection Test Performs Well in Real-World Asian Cohort
Subgroup Analysis Demonstrates Efficacy of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo